Document is current
Any future updates will be listed below
-
Authors
Goodwin, Pamela J. https://orcid.org/0000-0003-2637-6906
Dowling, Ryan J. O.
Ennis, Marguerite https://orcid.org/0000-0003-1094-5131
Chen, Bingshu E. https://orcid.org/0000-0001-6139-0696
Parulekar, Wendy R.
Shepherd, Lois E.
Burnell, Margot J.
Vander Meer, Rachel
Molckovsky, Andrea
Gurjal, Anagha
Gelmon, Karen A. https://orcid.org/0000-0003-4111-2757
Ligibel, Jennifer A.
Hershman, Dawn L. https://orcid.org/0000-0001-8807-153X
Mayer, Ingrid A.
Whelan, Timothy J.
Hobday, Timothy J.
Rastogi, Priya
Rabaglio-Poretti, Manuela
Lemieux, Julie
Thompson, Alastair M.
Rea, Daniel W.
Stambolic, Vuk
-
Funding
Funding for this research was provided by:
Ontario Institute for Cancer Research (10NOV-467)
- License Information
-
More Information
Article History
Received: 21 December 2020
Accepted: 3 May 2021
First Online: 8 June 2021
Competing interests
: Dr. Whelan reports non-financial support from Genomic Health, outside the submitted work. Dr. Ryan Dowling is currently an employee at Hoffmann-La Roche Limited, Mississauga, ON. Dr. Julie Lemieux reports honoraria from Novartis, Pfizer, Eli Lilly. Dr. Ingrid Mayer reports honoraria from Novartis, grants and personal fees from Pfizer, grants and personal fees from Genentech, personal fees from Lilly, personal fees from Puma, personal fees from Abbvie, personal fees from Immunomedics, personal fees from Macrogenics, personal fees from Seattle Genetics, personal fees from Astra-Zeneca, personal fees from GSK. All of these are outside the submitted work. The other authors report no competing interests.
